|
|
Other links at Articles > Allergy and Clinical Immunology |
| 3. |
Omalizumab Seen Safe, Effective in Children 6 to 11 Years
|
|
|
In children aged 6 to 11 years with inadequately controlled allergic asthma, adding the anti-IgE monoclonal antibody omalizumab (Xolair; Novartis) to optimized treatment leads to a clinically significant reduction in asthma attacks and is well tolerated. Reuters Health Information
|
| 5. |
Navigating in the Sea of Healthcare
|
|
|
Karen Donelan, ScD, Senior Scientist in Health Policy, Massachusetts General Hospital, addresses the morass of navigating healthcare.
The Medscape Journal of Medicine
|
|
|